Results 81 to 90 of about 4,744 (194)

New advances in DPYD genotype and risk of severe toxicity under capecitabine. [PDF]

PLoS ONE, 2017
Deficiency in dihydropyrimidine dehydrogenase (DPD) enzyme is the main cause of severe and lethal fluoropyrimidine-related toxicity. Various approaches have been developed for DPD-deficiency screening, including DPYD genotyping and phenotyping.
Marie-Christine Etienne-Grimaldi, Jean-Christophe Boyer, Christophe Beroud, Litaty Mbatchi, André van Kuilenburg, Christine Bobin-Dubigeon, Fabienne Thomas, Etienne Chatelut, Jean-Louis Merlin, Frédéric Pinguet, Christophe Ferrand, Judith Meijer, Alexandre Evrard, Laurence Llorca, Gilles Romieu, Philippe Follana, Thomas Bachelot, Loic Chaigneau, Xavier Pivot, Véronique Dieras, Rémy Largillier, Mireille Mousseau, Anthony Goncalves, Henri Roché, Jacques Bonneterre, Véronique Servent, Nadine Dohollou, Yann Château, Emmanuel Chamorey, Jean-Pierre Desvignes, David Salgado, Jean-Marc Ferrero, Gérard Milano   +32 more
doaj   +1 more source

Frequency and clinical impact of DPYD gene variants

Abstract Introduction and objective: The aim of this study was to determine the prevalence of loss-of-function variants in the DPYD gene in patients with solid tumours who have undergone genotyping and establish the clinical results of this implementation in clinical practice in four hospitals in the Balearic Islands. Methods: The study was descriptive,
GÓMEZ ZAMORA, M, LÓPEZ LÓPEZ-CEPERO, M, DO PAZO OUBIÑA, F, OBRADOR DE HEVIA, A, OLIVER NOGUERA, A, TRUJILLO RUIZ, A, CASTRO MANZANARES, M, GUILLOT MORALES, M   +7 more
openaire   +2 more sources

DPYD Genotyping, Fluoropyrimidine Dosage and Toxicity: An Umbrella Review of Systematic Reviews

Pharmaceuticals
Background/Objectives: Fluoropyrimidines are widely used chemotherapeutic agents in various solid tumors. Germline variants in the DPYD gene, which encodes the enzyme dihydropyrimidine dehydrogenase (DPD), are known to impair drug metabolism and increase
Sara Otero-Torres, Rosa Rodríguez-Mauriz, Eduard Fort-Casamartina, Ana Clopés-Estela, Francesc Soler-Rotllant, Sandra Fontanals-Martínez, Olalla Montero-Pérez   +6 more
doaj   +1 more source

Study of polymorphisms of UGT1A1 and DPYD genes in chemotherapy for colorectal cancer

Сибирский онкологический журнал, 2019
Background. The personalized approach implies an individual choice of medicines and their doses for the patient, providing the most effective and safe pharmacotherapy. Objective: analysis of the frequencies of UGT1A1 and DPYD polymorphisms and comparison
N. N. Timoshkina, O. A. Bogomolova, I. A. Zhuzhelenko, S. N. Kabanov, E. A. Kalabanova, I. S. Mitashok, Ya. V. Svetitskaya, D. I. Vodolazhskii   +7 more
doaj   +1 more source

Feasibility of DPYD Genotyping in Australian Cancer Patients

, 2023
Abstract Background. Fluoropyrimidine (FP) chemotherapies are widely prescribed for solid organ malignancies, including colorectal, gastrointestinal, breast and head and neck cancers. They are prescribed for over 10,000 Australian cancer patients per year.
Cassandra White, Christine Paul, Esther Liet, Dilshan Kalpage, David Mossman, Andrew Ziolkowski, Stephen Ackland, Rodney J. Scott   +7 more
openaire   +1 more source

Development and analytical validation of a targeted short‐read next generation sequencing‐based pharmacogenetic panel for comprehensive variant detection

British Journal of Pharmacology, Volume 183, Issue 16, Page 4735-4760, August 2026.
Abstract Background and Purpose Genomic profiling of patients for genetic variants that modify the effect of specific medications has many benefits, including the possibility of avoiding toxicities and ensuring an adequate effect of the medication. Our intention was to develop a comprehensive, high‐quality pharmacogenetic test panel for clinical use ...
Anna Gréen, Nils Johan Fredriksson, Michael Andresen, Jon Jonasson, Malin Lindqvist Appell, Henrik Gréen   +5 more
wiley   +1 more source

Pharmacogenetic Practice of Anticancer Drugs: Multiple Approaches for an Accurate and Comprehensive Genotyping

Pharmacogenomics and Personalized Medicine, 2023
Cristina Montrasio,1 Stefania Cheli,1 Emilio Clementi2,3 1Unit of Clinical Pharmacology, ASST Fatebenefratelli Sacco, L. Sacco University Hospital, Milan, Italy; 2Clinical Pharmacology Unit, Department of Biomedical and Clinical Sciences, L.
Montrasio C, Cheli S, Clementi E
doaj  

Near Miss or Standard of Care? DPYD Screening for Cancer Patients Receiving Fluorouracil

Current Oncology, 2020
5-fluorouracil (5-FU) and its pro-drug capecitabine are widely used anticancer agents. Most 5-FU catabolism is dependent on dihydropyrimidine dehydrogenase (DPD) encoded by the DPYD gene, and DPYD variants that reduce DPD function increase 5-FU toxicity.
Lauren E. Winquist, Michael Sanatani, Richard B. Kim, Eric Winquist   +3 more
doaj   +1 more source

Mutational spectrum of dihydropyrimidine dehydrogenase gene (DPYD) in the Tunisian population.

, 2007
Dihydropyrimidine dehydrogenase enzyme (DPD) deficiency is a pharmacogenetic syndrome leading to severe side-effects in patients receiving therapies containing the anticancer drug 5-fluorouracil (5-FU).
Ben Fredj, R;Gross, E;Chouchen, L;B'Chir, F;Ben Ahmed, S;Neubauer, S;Kiechle, M;Saguem, S
core   +1 more source

A Serverless Pharmacogenomic Risk Dashboard: Translating Ensemble Models and Model‐Based Scenario Rules to Clinical Decision Support

Clinical and Translational Science, Volume 19, Issue 8, August 2026.
ABSTRACT The “last mile” problem in healthcare AI—translating high‐performance models into accessible, privacy‐preserving point‐of‐care tools—remains unsolved for pharmacogenomic (PGx) risk assessment. No existing platform integrates opioid and polypharmacy risk scoring, model‐based scenario analysis, and CPIC‐based PGx patient cards within a single ...
R. Jerome Dixon, Elvin T. Price
wiley   +1 more source